低分子肝素钙治疗肾病综合征疗效和安全性

Efficacy and Safety of Low Molecular Weight Heparin Calcium in the Treatment of Nephrotic Syndrome

目的评价低分子肝素钙治疗肾病综合征的疗效,为临床治疗肾病综合征提供参考。方法方便选取2013年3月-2017年3月到该院肾内科就诊的82例肾病综合征患者作为研究对象,按照双色球随机分组法分为两组,对照组40例采用常规治疗,观察组42例在常规治疗基础上采用低分子肝素钙治疗,对两组患者的疗效、生化指标、不良反应进行比较分析。结果观察组的总有效率76.19%明显高于对照组52.50%,经比较,两组差异有统计学意义(t=8.236,P<0.05);经过治疗后,据数据显示,观察组肾病综合征患者治疗后的PT、APTT、FIB、DD等指标为(19.28±2.14)s、(39.68±3.71)s、(3.68±1.21)g/L、(5.07±2.41)mg/L变化情况明显优于对照组(10.65±2.21)s、(20.18±2.51)s、(2.08±1.01)g/L、(11.65±3.54)mg/L肾病综合征患者,经比较,两组差异有统计学意义(t=4.168、4.026、2.665、3.687,P<0.05);观察组不良反应发生率为4.76%(2/42),包括1例血压升高,1例蛋白质代谢异常;对照组不良反应发生率为12.50%(5/40),包括2例血压升高,2例蛋白质代谢异常,1例肾上腺皮质功能异常,经比较,两组患者不良反应率比较差异有统计学意义(χ^2=4.012,P<0.05)。结论临床治疗肾病综合征可考虑在常规治疗基础之上加用低分子肝素钙,有助于改善患者肾功能,提高疗效,且用药安全。不良反应小,可在临床广泛推广。

Objective To evaluate the efficacy of low molecular weight heparin calcium in the treatment of nephrotic syndrome, and to provide a reference for the clinical treatment of nephrotic syndrome. Methods Eighty-two patients with nephrotic syndrome who were admitted to the Department of Nephrology of our hospital from March 2013 to March 2017 were conveniently selected. The patients were divided into two groups according to the two-color ball randomization method.The control group was treated with conventional therapy. On the basis of conventional treatment, low molecular weight heparin calcium was used to compare the curative effect, biochemical index and adverse reactions of the two groups.Results The total effective rate of the observation group was 76.19%, which was significantly higher than that of the control group(52.50%). There were significant statistical differences between the two groups(t=8.236, P<0.05). After treatment,according to the data, the indicators of PT, APTT, FIB, DD, etc. after treatment in patients with nephrotic syndrome were(19.28±2.14)s,(39.68±3.71)s,(3.68±1.21)g/L,(5.07±2.41)g/L were significantly better than those of the control group(10.65 ±2.21)s,(20.18 ±2.51)s,(2.08 ±1.01)g/L,(1 1.65 ±3.54)mg/L nephrotic syndrome. After comparison, there was a statistically significant difference between the two groups(t=4.168, 4.026, 2.665, 3.687, P<0.05);the incidence of adverse reactions in the observation group was 4.76%(2/42), including 1 case of elevated blood pressure. 1 case of abnormal protein metabolism;the control group of the incidence of reaction was 12.50%(5/40), including 2 cases of elevated blood pressure, 2 cases of abnormal protein metabolism, and 1 case of adrenal cortical dysfunction. After comparison, there was a statistically significant difference in the adverse reaction rate between the two groups(χ^2= 4.012, P <0.05). Conclusion Clinical treatment of nephrotic syndrome can be based on the addition of low molecular weight heparin calcium on the basis of conventional treatment, which can improve the renal function of patients, improve the efficacy, and safe medication. The adverse reactions are small and can be widely promoted in the clinic.